{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:07:12Z","timestamp":1794236832040,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pukou Branch Hospital of Jiangsu Province Hospital (Nanjing PuKou People's Hospital) General Project of Science and Technology Development Fund in 2021","award":["KJ2021-22"],"award-info":[{"award-number":["KJ2021-22"]}]},{"name":"Nanjing Medical University Project of Science and Technology Development Fund in 2024","award":["NMUB20240286"],"award-info":[{"award-number":["NMUB20240286"]}]},{"name":"Jiangsu Health Vocational College School-Level Research Project in 2024","award":["YJXT-PR202409"],"award-info":[{"award-number":["YJXT-PR202409"]}]},{"name":"Innovation Funds from the Chinese Society of Clinical Oncology Youth Committee","award":["Y-young2019-060"],"award-info":[{"award-number":["Y-young2019-060"]}]},{"name":"the Joint Research Project by Southeast University and Nanjing Medical University","award":["3207027381"],"award-info":[{"award-number":["3207027381"]}]},{"name":"Nanjing special fund for health science and technology development in 2020","award":["YKK20208"],"award-info":[{"award-number":["YKK20208"]}]},{"name":"Pukou Branch Hospital of Jiangsu Province Hospital (Nanjing PuKou People's Hospital) Major Project of Science and Technology Development Fund in 2021","award":["KJ2021-1"],"award-info":[{"award-number":["KJ2021-1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-025-02097-5","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T13:45:01Z","timestamp":1741959901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive clinical and genetic characterization of hyperprogressive biliary tract cancer during PD-1 blockade monotherapy: case report and literature review"],"prefix":"10.1186","volume":"18","author":[{"given":"Kang-Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-Yuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"2097_CR1","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2147\/OTT.S269671","volume":"14","author":"PK Seesaha","year":"2021","unstructured":"Seesaha PK, Wang KX, Wang GQ, Cui TY, Zhao FJ, Pan LL, et al. Current progress and future perspectives of Immune checkpoint inhibitors in biliary Tract Cancer. Onco Targets Ther. 2021;14:1873\u201382.","journal-title":"Onco Targets Ther"},{"issue":"10272","key":"2097_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"8","key":"2097_CR3","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1002\/ijc.33013","volume":"147","author":"SA Piha-Paul","year":"2020","unstructured":"Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190\u20138.","journal-title":"Int J Cancer"},{"issue":"8","key":"2097_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2468-1253(19)30086-X","volume":"4","author":"M Ueno","year":"2019","unstructured":"Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611\u201321.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2097_CR5","doi-asserted-by":"crossref","unstructured":"Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q et al. Camrelizumab plus Gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-001240"},{"key":"2097_CR6","doi-asserted-by":"crossref","unstructured":"Chen X, Wang D, Liu J, Qiu J, Zhou J, Ying J et al. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. J Immunother Cancer. 2021;9(11).","DOI":"10.1136\/jitc-2021-003214"},{"issue":"4","key":"2097_CR7","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/hep.31862","volume":"74","author":"JG Yoon","year":"2021","unstructured":"Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, et al. Molecular characterization of biliary Tract Cancer predicts chemotherapy and programmed death 1\/Programmed death-ligand 1 blockade responses. Hepatology. 2021;74(4):1914\u201331.","journal-title":"Hepatology"},{"issue":"5","key":"2097_CR8","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1002\/ctm2.167","volume":"10","author":"XJ Han","year":"2020","unstructured":"Han XJ, Alu A, Xiao YN, Wei YQ, Wei XW. Hyperprogression: a novel response pattern under immunotherapy. Clin Transl Med. 2020;10(5):e167.","journal-title":"Clin Transl Med"},{"issue":"13","key":"2097_CR9","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-17-2310","volume":"24","author":"Z Yang","year":"2018","unstructured":"Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, et al. Investigating Novel Resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor Osimertinib in Non-small Cell Lung Cancer patients. Clin Cancer Res. 2018;24(13):3097\u2013107.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2097_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41598-017-00520-1","volume":"7","author":"Y Shu","year":"2017","unstructured":"Shu Y, Wu X, Tong X, Wang X, Chang Z, Mao Y, et al. Circulating tumor DNA mutation profiling by targeted next generation sequencing provides Guidance for personalized treatments in multiple Cancer types. Sci Rep. 2017;7(1):583.","journal-title":"Sci Rep"},{"issue":"15","key":"2097_CR11","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114\u201320.","journal-title":"Bioinformatics"},{"issue":"16","key":"2097_CR12","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16):e131.","journal-title":"Nucleic Acids Res"},{"issue":"23","key":"2097_CR13","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1093\/bioinformatics\/btu549","volume":"30","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, Stehr H, Lee LJ, Liu CL, Diehn M, et al. FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics. 2014;30(23):3390\u20133.","journal-title":"Bioinformatics"},{"issue":"11","key":"2097_CR14","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.30642","volume":"123","author":"DB Johnson","year":"2017","unstructured":"Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123(11):1904\u201311.","journal-title":"Cancer"},{"issue":"1","key":"2097_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12943-020-01200-x","volume":"19","author":"X Wang","year":"2020","unstructured":"Wang X, Wang F, Zhong M, Yarden Y, Fu L. The biomarkers of hyperprogressive disease in PD-1\/PD-L1 blockage therapy. Mol Cancer. 2020;19(1):81.","journal-title":"Mol Cancer"},{"issue":"3","key":"2097_CR16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, et al. Antibody-Fc\/FcR Interaction on macrophages as a mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer subsequent to PD-1\/PD-L1 blockade. Clin Cancer Res. 2019;25(3):989\u201399.","journal-title":"Clin Cancer Res"},{"key":"2097_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12885-015-1397-4","volume":"15","author":"B Robl","year":"2015","unstructured":"Robl B, Pauli C, Botter SM, Bode-Lesniewska B, Fuchs B. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy. BMC Cancer. 2015;15:379.","journal-title":"BMC Cancer"},{"issue":"6","key":"2097_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.4161\/cbt.28411","volume":"15","author":"RC Wu","year":"2014","unstructured":"Wu RC, Wang TL, Shih Ie M. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther. 2014;15(6):655\u201364.","journal-title":"Cancer Biol Ther"},{"key":"2097_CR19","doi-asserted-by":"publisher","first-page":"e12750","DOI":"10.7717\/peerj.12750","volume":"10","author":"S Tessiri","year":"2022","unstructured":"Tessiri S, Techasen A, Kongpetch S, Namjan A, Loilome W, Chan-On W, et al. Therapeutic targeting of ARID1A and PI3K\/AKT pathway alterations in cholangiocarcinoma. PeerJ. 2022;10:e12750.","journal-title":"PeerJ"},{"issue":"10","key":"2097_CR20","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1002\/ijc.31979","volume":"144","author":"Y Sheng","year":"2019","unstructured":"Sheng Y, Wei J, Zhang Y, Gao X, Wang Z, Yang J, et al. Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma. Int J Cancer. 2019;144(10):2440\u201352.","journal-title":"Int J Cancer"},{"key":"2097_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fimmu.2020.00492","volume":"11","author":"M Denis","year":"2020","unstructured":"Denis M, Duruisseaux M, Brevet M, Dumontet C. How can Immune checkpoint inhibitors cause Hyperprogression in Solid tumors? Front Immunol. 2020;11:492.","journal-title":"Front Immunol"},{"issue":"12","key":"2097_CR22","first-page":"1455","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Santoni M, Mollica V, Logullo F, Rosellini M, Marchetti A, et al. Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Cancer Med. 2021;17(12):1455\u201366.","journal-title":"Cancer Med"},{"issue":"21","key":"2097_CR23","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/cancers16213689","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Ayasun R, Rizzo A, Guven DC. Prognostic Value of Neutrophil-to-Eosinophil ratio (NER) in Cancer: a systematic review and Meta-analysis. Cancers (Basel). 2024;16(21):3689.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2097_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17474124.2021.1853527","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;15(5):527\u201336.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10","key":"2097_CR25","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/cancers16101835","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Rizzo A, Aksoy S, Guven DC. Prognostic significance of the Royal Marsden Hospital (RMH) score in patients with Cancer: a systematic review and Meta-analysis. Cancers (Basel). 2024;16(10):1835.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2097_CR26","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive Disease is a New Pattern of Progression in Cancer patients treated by Anti-PD-1\/PD-L1. Clin Cancer Res. 2017;23(8):1920\u20138.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2097_CR27","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Saada-Bouzid","year":"2017","unstructured":"Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605\u201311.","journal-title":"Ann Oncol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02097-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T13:45:30Z","timestamp":1741959930000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-025-02097-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2097"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02097-5","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by relevant regulatory and independent ethics committee of the First Affiliated Hospital with Nanjing Medical University and done in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. The written informed consent for the publication of clinical details and images was obtained from the patient and his family members. Patient identification and other personal information that could be used to reveal the identity of the patient were protected. The case details and images were approved for publication by the First Affiliated Hospital of Nanjing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}